Last week, Calithera Biosciences listed 8 million shares on the NASDAQ under the symbol CALA, raising $80 million in its IPO after pricing below its estimated range. Its stock closed at $9.41 on Friday, giving the company a market cap of about $168 million. Calithera is an early stage biotech developing treatments to inhibit the metabolism of cancerous tumors. Prior to the offering, the company had raised nearly $80 million in VC, garnering a valuation of $99 million in July of this year. Delphi Ventures held on to 13.6% of Calithera stake post-offering, while Morgenthaler (12.1%) and Advanced Technology Ventures (11.8%) also remain invested.